Recent studies have demonstrated that cell proliferation- and apoptosis-associated biomarkers are useful for predicting the clinical outcomes of patients with bladder urothelial carcinoma.[1] The cell proliferation marker Ki-67 is a nuclear antigen expressed in the S, G1, G2, and M phases of the cell cycle. This evidence concerns the gene MKI67 and bladder transitional cell carcinoma.